Transgene S.a.

Michel Geist

Christine Thioudellet

Jean-Baptiste Marchand

Benoît Grellier

Hélène Haegel

Nathalie Silvestre

Karola Rittner

Philippe Erbs

Jean-Marc Balloul

Stephane Paul

Stéphane Paul

Jean Marc Balloul

Hèléne Haegel

Nathalle Silvestre

Helene Haegel

The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.

Oncolytic virus for expression of immune checkpoint modulators

The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.

Antibody against the CSF-1R

The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.

Poxvirus with targeted infection specificity

Growing community of inventors

Brumath, France

Michel Geist